Roughly one in three patients with biomarker-confirmed early Alzheimer's disease attending a routine memory clinic also carried detectable alpha-synuclein seeds in their spinal fluid, according to a prospective single-centre study published in Alzheimer's & Dementia in March 2026. Researchers led by Tamara Shiner and Noa Bregman at the Cognitive Neurology Unit of Tel Aviv Medical Center evaluated 108 people with mild cognitive impairment or mild dementia due to suspected Alzheimer's disease who were undergoing lumbar puncture to assess eligibility for anti-amyloid therapy. Of the 65 whose spinal fluid confirmed Alzheimer's biology, 21 (32.3 per cent) were positive on the alpha-synuclein seed amplification assay, the laboratory test that amplifies tiny quantities of misfolded protein of the kind found in Lewy body disease and Parkinson's disease.
The point of the study is the population, not the assay. Previous estimates of Lewy co-pathology in Alzheimer's disease have come largely from autopsy series and from curated research cohorts. Here the participants were consecutive clinic patients being screened for treatment, and the authors report that none had a clinically suspected synucleinopathy on specialist neurological assessment; dementia with Lewy bodies and Parkinson's disease dementia were explicitly excluded. Seed positivity was associated with self-reported loss of smell (P = 0.004) and with slightly older age at lumbar puncture (74.71 years against 71.25 years, P = 0.050). Cognitive scores, questionnaire scores and Alzheimer's biomarker levels did not differ between the positive and negative groups. Within the positive group, participants with features of rapid eye movement sleep behaviour disorder showed faster seeding kinetics in the assay, on an analysis adjusted for age, sex and spinal fluid protein.
The authors are careful about the figure's direction of error. In sporadic Alzheimer's disease, alpha-synuclein pathology is most prominent in the amygdala, and the spinal fluid assay is less sensitive to amygdala-predominant deposits, so they write that 32 per cent is likely to be an underestimate, consistent with the higher rates seen at post mortem. The counterpoint is that a positive assay is not a diagnosis of a second disease: it marks the presence of seeding-competent protein, and this cohort was cross-sectional, with no autopsy confirmation and no outcome data. Independent work published in the same journal in January 2026 reported that quantitative versions of the assay track cognitive performance and dementia conversion, which is the kind of prognostic evidence the Tel Aviv snapshot does not yet supply.
The finding lands in the population now being triaged for lecanemab and donanemab, where clinicians already ask whether mixed pathology changes what a treated patient can expect. The Tel Aviv team states plainly that longitudinal follow-up is required to test whether assay status predicts response to anti-amyloid therapies. Nothing in the paper supports withholding or altering treatment on the basis of a seed result, and the assay is not part of eligibility criteria for those drugs.